Horizon Pharma in $800M Raptor rare disease buy, but pipeline beset by failures : fiercebiotech

As it stated in fiercebiotech

Horizon Pharma in $800M Raptor rare disease buy, but pipeline beset by failures

Horizon Pharma in $800M Raptor rare disease buy, but pipeline beset by failures

Ireland's Horizon Pharma ($HZNP) will pay a 21% premium for California-based Raptor Pharmaceutical as it looks to bolster its rare disease portfolio while also expanding its geographical footprint.But it will also gain a tough pipeline that has been hit by failures over the past year.The deal, which is worth $9 a share--or around $800 million--will see Horizon gain access to Procysbi (cysteamine bitartrate) for the orphan condition nephropathic (kidney) cystinosis, as well as Quinsair, which is licensed in Europe and Canada to help manage chronic pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis.The merger will also diversify Horizon's revenue with 11 medicines across three business units, namely in orphan, rheumatology and primary care--as well as bolstering its rare disease revenue, which in the first 6 months of 2016 was nearly half of Horizon's total revenue.


coupled with usatoday

Horizon Pharma buys Raptor for $800 million in rare disease business deal

Horizon Pharma buys Raptor for $800 million in rare disease business deal

Horizon Pharma deal to buy Raptor targets rare disease business.(Photo: Thinkstock)Horizon Pharma (HZNP) announced on Monday that it is acquiring fellow drugmaker Raptor Pharmaceutical (RPTP) for $800 million.The deal, due to close in the fourth quarter, is set to bump up Horizon's portfolio of drugs for rare diseases.Adding Raptor also helps Horizon as it looks to expand to Europe and other markets internationally.


in the same way washingtontimes

Horizon Pharma to pay $800M for rare disease drug developer

Horizon Pharma to pay $800M for rare disease drug developer

Horizon Pharma will spend about $800 million to buy Raptor Pharmaceutical and expand its portfolio of rare disease treatments, a growing area of focus for drugmakers.The Ireland-based drug developer said Monday that the deal will strengthen its business in the United States and provide a platform to expand in Europe and other international markets.Raptor's portfolio includes Procysbi, which treats a rare metabolic disorder, and Quinsair, approved for managing a chronic pulmonary infection in adult patients with cystic fibrosis.Horizon Pharma Plc.